Clinical Trials
96 trialsA Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
GlaxoSmithKline
MK-2140-010
Merck Sharp & Dohme LLC
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
Fern-EC-01
BioNTech SE
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
AstraZeneca
OLYMPIA-1
Regeneron Pharmaceuticals
SaLuDo
PharmaMar
OLYMPIA-3
Regeneron Pharmaceuticals
POLARIX
Hoffmann-La Roche
EPCOREâ„¢FL-2
Genmab
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
LEDA
Novartis
DEB
Chipscreen Biosciences, Ltd.
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shanghai JMT-Bio Inc.
TroFuse-005
Merck Sharp & Dohme LLC
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
AstraZeneca
frontMIND
Incyte Corporation
ESCALADE
Acerta Pharma BV
MK-3475-775
Eisai Inc.
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
AstraZeneca
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Hoffmann-La Roche
GOLSEEK-1
Celgene
OLYMPIA-2
Regeneron Pharmaceuticals
ASCENT-GYN-01
Gilead Sciences
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Hansoh BioMedical R&D Company
APHINITY
Hoffmann-La Roche
MK-3475-522
Merck Sharp & Dohme LLC
CRESCENDO
Acrotech Biopharma Inc.
ZUMA-22
Gilead Sciences
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Chipscreen Biosciences, Ltd.
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
ARTISTRY-7
Mural Oncology, Inc
ANNOUNCE
Eli Lilly and Company
KEYNOTE-756
Merck Sharp & Dohme LLC
SELENE
Janssen Research & Development, LLC
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC
EPCORE DLBCL-2
Genmab
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Hutchmed
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
CHRONOS-4
Bayer
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Hoffmann-La Roche
IMpassion050
Hoffmann-La Roche
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
FeDeriCa
Hoffmann-La Roche
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
ImmunityBio, Inc.
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
Samyang Biopharmaceuticals Corporation
FIBROSARC
Philogen S.p.A.